Yu Henghai, Bai Yitao, Xu Chang, He Xin, Liu Qin, Ma Dou, A Yongjun
Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, Guangxi.
Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Medicine (Baltimore). 2020 Nov 13;99(46):e21291. doi: 10.1097/MD.0000000000021291.
Small ubiquitin-like modifier 1 pseudogene 3 (SUMO1P3) is a novel identified long non-coding RNA that is upregulated in several cancers and exerts its oncogenic effects via multiple pathways. SUMO1P3 was significantly higher in HCC tissues and cells than in non-cancerous specimens and normal cells. SUMO1P3 knockdown inhibited the proliferation, migration, and invasion of HCC cells. In the present study, we investigated the clinical significance and prognostic value of SUMO1P3 in HCC.A total of 123 patients were pathologically diagnosed as primary HCC and underwent surgical resection at the Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University from March 2014 to November 2019. The expression differences between HCC tissues and matched normal tissues were analyzed using paired Student's t test. Chi-squared test was used for correlation analysis. Survival curves were plotted using the Kaplan-Meier method and were compared via the log-rank test. The independent prognostic value of SUMO1P3 expression was evaluated using results from univariate and multivariate Cox regression models.As revealed by quantitative RT-PCR analysis, SUMO1P 3 expression level was significantly higher in HCC cancer tissues compared with normal adjacent tissues (mean ± SD: 4.341 ± 1.320 vs 1.000 ± 0.3666, P < .001). The χ test showed that the SUMO1P 3 expression level was significantly associated with tumor size (P = .031), capsular invasion (P = .011), vascular invasion (P = .004), Edmondson-Steiner grade (P = .002), and TNM stage (P = .001). The patients with high SUMO1P 3 expression showed shorter 5-year overall survival than those with low SUMO1P 3 expression (P = .034; log-rank test). Multivariate regression analysis showed that the status of SUMO1P 3 expression was an independent prognostic factor for overall survival (HR = 2.107, 95% CI: 1.478-9.014, P = .031).The expression levels of SUMO1P 3 may be a reliable prognostic biomarker to predict the clinical outcomes in patients with HCC.
小泛素样修饰物1假基因3（SUMO1P3）是一种新发现的长链非编码RNA，在多种癌症中上调，并通过多种途径发挥致癌作用。SUMO1P3在肝癌组织和细胞中的表达明显高于癌旁组织和正常细胞。敲低SUMO1P3可抑制肝癌细胞的增殖、迁移和侵袭。在本研究中，我们探讨了SUMO1P3在肝癌中的临床意义和预后价值。
2014年3月至2019年11月，昆明医科大学第二附属医院肝胆胰外科共有123例经病理诊断为原发性肝癌并接受手术切除的患者。采用配对t检验分析肝癌组织与配对正常组织之间的表达差异。采用卡方检验进行相关性分析。采用Kaplan-Meier法绘制生存曲线，并通过对数秩检验进行比较。使用单因素和多因素Cox回归模型的结果评估SUMO1P3表达的独立预后价值。
定量RT-PCR分析显示，与癌旁正常组织相比，肝癌组织中SUMO1P3表达水平显著升高（平均值±标准差：4.341±1.320 vs 1.000±0.3666，P<.001）。卡方检验显示，SUMO1P3表达水平与肿瘤大小（P=.031）、包膜侵犯（P=.011）、血管侵犯（P=.004）、Edmondson-Steiner分级（P=.002）和TNM分期（P=.001）显著相关。SUMO1P3高表达患者的5年总生存率低于SUMO1P3低表达患者（P=.034；对数秩检验）。多因素回归分析显示，SUMO1P3表达状态是总生存的独立预后因素（HR=2.107，95%CI：1.478-9.014，P=.031）。
SUMO1P3的表达水平可能是预测肝癌患者临床结局的可靠预后生物标志物。
